SynthesisClinical drug investigation2019
Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review.
Synthesis in Clinical drug investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Beta-blocker treatment in the critically ill: a systematic review and meta-analysis.Annals of medicine · 2022Pooled it
- Beta-blockers in adults with acute traumatic brain injury: a systematic review and meta-analysis of randomized controlled trials.Journal of anesthesia, analgesia and critical care · 2025Review
- Article
- Impact of premorbid use of beta‑blockers on survival outcomes of patients with sepsis: A systematic review and meta‑analysis.Experimental and therapeutic medicine · 2024Article
- The role of beta-blocker drugs in critically ill patients: a SIAARTI expert consensus statement.Journal of anesthesia, analgesia and critical care · 2023Article
- The influence of metoprolol in patients with sepsis-induced cardiomyopathy: A retrospective study.Saudi medical journal · 2023Article
- A nationwide analysis on the interaction between frailty and beta-blocker therapy in hip fracture patients.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2023Article
- Role of aspirin, beta-blocker, statins, and heparin therapy in septic patients under mechanical ventilation: a narrative review.Frontiers in medicine · 2023Review
- Premorbid use of selective beta-blockers improves sepsis incidence and course: Human cohort and animal model studies.Frontiers in medicine · 2023Article
- Beta-blockers in septic shock: What is new?Journal of intensive medicine · 2022Review
- Low-Dose Propranolol Prevents Functional Decline in Catecholamine-Induced Acute Heart Failure in Rats.Toxics · 2022Article
- Is the Sympathetic System Detrimental in the Setting of Septic Shock, with Antihypertensive Agents as a Counterintuitive Approach? A Clinical Proposition.Journal of clinical medicine · 2021Review
- [Pharmacological therapy of circulatory shock].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2021Article
- Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study.Journal of clinical medicine · 2021Article
- Hemodynamic and anti-inflammatory effects of early esmolol use in hyperkinetic septic shock: a pilot study.Critical care (London, England) · 2021Article
- Beta-Adrenergic Blockade in Critical Illness.Frontiers in pharmacology · 2021Review
- The Efficacy and Safety of Esmolol for Septic Shock: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis and septic shock are inflammatory disorders associated with high rates of mortality. Patients with sepsis and septic shock frequently become tachycardic as a result of the utilization of vasopressor therapy and cardiac overcompensation owing to hypotension, predisposing patients to an increased risk of atrial fibrillation. Previously, it was thought that beta-blocker therapy in patients with sepsis would exacerbate hypotension; however, recent studies have shown that may not be the case.
objectiveThis review aims to ascertain whether beta-blocker therapy reduces heart rate in patients with sepsis without a corresponding decrease in blood pressure, and if beta-blockade has a beneficial effect on mortality.
methodsSeveral databases including Cochrane, EMBASE, PubMed, SCOPUS, and Web of Science were scoured for trials pertaining to the utilization of beta-blockers in sepsis and septic shock, and trials that were either prospective or controlled were included in this review.
resultsIn the initial search, 1839 articles were found, and those were subsequently reduced to 14 trials (five randomized controlled trials, nine non-randomized trials) that were deemed appropriate for inclusion in this review. All included trials displayed beneficial effects on heart rate without any detriments to blood pressure. Of the six trials that assessed mortality, four showed substantial benefits.
conclusionThe majority of the trials assessed in this review displayed beneficial results for beta-blocker use in patients with sepsis. However, owing to the deficit of large-scale randomized controlled trials addressing this topic, further research is needed to ensure the veracity of these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.